



Modular Program Report

The following report(s) provides findings from an FDA-initiated query using its Mini-Sentinel pilot. While Mini-Sentinel queries may be undertaken to assess potential medical product safety risks, they may also be initiated for various other reasons. Some examples include determining a rate or count of an identified health outcome of interest, examining medical product use, exploring the feasibility of future, more detailed analyses within Mini-Sentinel, and seeking to better understand the capabilities of the Mini-Sentinel pilot.

Data obtained through Mini-Sentinel are intended to complement other types of evidence such as preclinical studies, clinical trials, postmarket studies, and adverse event reports, all of which are used by FDA to inform regulatory decisions regarding medical product safety. The information contained in this report is provided as part of FDA's commitment to place knowledge acquired from the Mini-Sentinel pilot in the public domain as soon as possible. Any public health actions taken by FDA regarding products involved in Mini-Sentinel queries will continue to be communicated through existing channels.

FDA wants to emphasize that the fact that FDA has initiated a query involving a medical product and is reporting findings related to that query does not mean that FDA is suggesting health care practitioners should change their prescribing practices for the medical product or that patients taking the medical product should stop using it. Patients who have questions about the use of an identified medical product should contact their health care practitioners.

The following report contains a description of the request, request specifications, and results from the modular program run(s).

If you are using a web page screen reader and are unable to access this document, please contact the Mini-Sentinel Operations Center for assistance at info@mini-sentinel.org.

Overview	
Request Description	<p>These results were generated using Mini-Sentinel Modular Program #3 Version 1.2. Each of the 16 Data Partners who responded to the request ran the program a total of 3 times (once for each of the 3 pre-existing condition groups). The query was run against the Mini-Sentinel Distributed Database and was distributed on October 13, 2011.</p> <p>Results provide counts of incident users, dispensings, and total days supplied of Suboxone, Subutex, Buprenex, Butrans, Generic Oral Buprenorphine, Generic Injectable Buprenorphine, and Generic Powder Buprenorphine with a washout periods of 0 days. The maximum allowable treatment gap was set to 14 days, the minimum episode duration and the minimum episode days supplied were set to zero. The program was run from January 1, 2009 to December 31, 2010. The care setting group was for outpatient only. The program was restricted to patients with pre-existing diagnosis codes falling into one of three groups: addiction, pain, or other. The pre-existing condition lookup period was set at 90 days from the drug index date.</p> <p>Please review the Notes below and refer to the Modular Program request for request specifications.</p>
Request ID	MSY3_MPR17
Specifications	
Table 1	Request specifications
Table 1	Three tables that include (by drug product) the number of users, number of dispensings, and total days supplied overall and stratified by age group, sex, and year for each of the pre-existing condition groups
Table 2	Number of users by drug product and pre-existing condition group in two tables stratified by age group and sex
Table 3	Number of days supplied by drug product and pre-existing condition group in two tables stratified by age group and sex
Table 4	Number of dispensings by drug product and pre-existing condition group in two tables stratified by age group and sex
Table 5	Days supplied per user by drug product and pre-existing condition group in two tables stratified by age group and sex
Table 6	Dispensings per user by drug product and pre-existing condition group in two tables stratified by age group and sex
Table 7	Days supplied per dispensing by drug product and pre-existing condition group in two tables stratified by age group and sex
Appendix A	ICD-9-CM Codes for each pre-existing condition group
Notes:	<p>The program was run for the entire time period. When examining the yearly stratification, note once an incident user is first encountered, this user will not be counted for subsequent years.</p> <p>As requested, new users were defined as users with no history of use of that specific buprenorphine drug product (as opposed to a history of any buprenorphine product). Thus, summing across all buprenorphine products may lead to double counting of users.</p> <p>Please contact the Mini-Sentinel Operations Center (MSOC_Requests@harvardpilgrim.org) for questions and to provide comments/suggestions for future enhancements to this document.</p>

Modular Program Specifications

Modular Program #3 was used to investigate the use of Buprenorphine products both separately and as one drug category among all members with pre-existing addiction-related, pain-related diagnoses, and other defined diagnoses. The program was run from January 1, 2009 to December 31, 2010. A washout period of 0 days was used to estimate prevalent use. The maximum allowable treatment gap was set to 14 days, and the minimum episode duration and the minimum episode days supplied were set to zero days. The program was run for users with pre-existing diagnosis codes falling into one of three groups: addiction, pain, or other. The pre-existing condition lookup period was set at 90 days from the drug index date. Age groups were split as follows: 0-17, 18-64, and 65+ years. In total, 21 different scenarios were examined in this report with differing pre-existing conditions and drug product groups. See below for a description of each of these scenarios.

Scenario	Query Start Date	Query End Date	Drug/Exposure Criteria					Pre-Existing Condition Criteria				
			Incident Exposure	Washout (days)	Episode Duration (days)	Min Days Supplied	Episode Gap (days)	Pre-Existing Condition*	Care Setting	Principal Dx?	Lookback Type	Lookback Period (days)
1	1/1/2009	12/31/2010	Buprenex	0	0	0	14	Addiction	Outpatient	No	Fixed	90
2	1/1/2009	12/31/2010	Butrans	0	0	0	14	Addiction	Outpatient	No	Fixed	90
3	1/1/2009	12/31/2010	Suboxone	0	0	0	14	Addiction	Outpatient	No	Fixed	90
4	1/1/2009	12/31/2010	Subutex	0	0	0	14	Addiction	Outpatient	No	Fixed	90
5	1/1/2009	12/31/2010	Generic Buprenorphine - Injectable	0	0	0	14	Addiction	Outpatient	No	Fixed	90
6	1/1/2009	12/31/2010	Generic Buprenorphine - Oral	0	0	0	14	Addiction	Outpatient	No	Fixed	90
7	1/1/2009	12/31/2010	Generic Buprenorphine - Powder	0	0	0	14	Addiction	Outpatient	No	Fixed	90
8	1/1/2009	12/31/2010	Buprenex	0	0	0	14	Pain	Outpatient	No	FIXED	90
9	1/1/2009	12/31/2010	Butrans	0	0	0	14	Pain	Outpatient	No	Fixed	90
10	1/1/2009	12/31/2010	Suboxone	0	0	0	14	Pain	Outpatient	No	Fixed	90
11	1/1/2009	12/31/2010	Subutex	0	0	0	14	Pain	Outpatient	No	Fixed	90
12	1/1/2009	12/31/2010	Generic Buprenorphine - Injectable	0	0	0	14	Pain	Outpatient	No	Fixed	90
13	1/1/2009	12/31/2010	Generic Buprenorphine - Oral	0	0	0	14	Pain	Outpatient	No	Fixed	90
14	1/1/2009	12/31/2010	Generic Buprenorphine - Powder	0	0	0	14	Pain	Outpatient	No	Fixed	90
15	1/1/2009	12/31/2010	Buprenex	0	0	0	14	Other	Outpatient	No	FIXED	90
16	1/1/2009	12/31/2010	Butrans	0	0	0	14	Other	Outpatient	No	Fixed	90
17	1/1/2009	12/31/2010	Suboxone	0	0	0	14	Other	Outpatient	No	Fixed	90
18	1/1/2009	12/31/2010	Subutex	0	0	0	14	Other	Outpatient	No	Fixed	90
19	1/1/2009	12/31/2010	Generic Buprenorphine - Injectable	0	0	0	14	Other	Outpatient	No	Fixed	90
20	1/1/2009	12/31/2010	Generic Buprenorphine - Oral	0	0	0	14	Other	Outpatient	No	Fixed	90
21	1/1/2009	12/31/2010	Generic Buprenorphine - Powder	0	0	0	14	Other	Outpatient	No	Fixed	90

*See Appendix A for a list of ICD-9 codes for each pre-existing condition

Table 1a. Number of Users, Number of Dispensings, and Total Days Supplied by Drug Product, Age Group, Sex, and Year for Pre-Existing Condition Group - Addiction

			Unique Patients	Dispensings	Total Days Supplied
Buprenex	<i>TOTAL</i>	<i>TOTAL</i>	5	58	1,020
	AGE GROUP	0 to 17 years	0	0	0
		18 to 64 years	5	58	1,020
		65+ years	0	0	0
	SEX	F	2	9	139
		M	3	49	881
		U	0	0	0
	INDEX YEAR	2009	4	50	883
2010		1	8	137	
Butrans	<i>TOTAL</i>	<i>TOTAL</i>	0	0	0
	AGE GROUP	0 to 17 years	0	0	0
		18 to 64 years	0	0	0
		65+ years	0	0	0
	SEX	F	0	0	0
		M	0	0	0
		U	0	0	0
	INDEX YEAR	2009	0	0	0
2010		0	0	0	
Suboxone	<i>TOTAL</i>	<i>TOTAL</i>	18,737	150,076	3,236,579
	AGE GROUP	0 to 17 years	91	490	9,380
		18 to 64 years	18,453	148,437	3,200,080
		65+ years	193	1,149	27,119
	SEX	F	7,250	55,041	1,176,764
		M	11,446	94,797	2,054,277
		U	41	238	5,538
	INDEX YEAR	2009	12,983	118,426	2,640,365
2010		5,754	31,650	596,214	
Subutex	<i>TOTAL</i>	<i>TOTAL</i>	1,410	5,812	109,902
	AGE GROUP	0 to 17 years	6	12	288
		18 to 64 years	1,381	5,710	107,277
		65+ years	23	90	2,337
	SEX	F	733	3,304	63,298
		M	677	2,508	46,604
		U	0	0	0
	INDEX YEAR	2009	1,114	4,833	95,044
2010		296	979	14,858	
Generic Buprenorphine - Injectable	<i>TOTAL</i>	<i>TOTAL</i>	6	6	46
	AGE GROUP	0 to 17 years	0	0	0
		18 to 64 years	6	6	46
		65+ years	0	0	0
	SEX	F	3	3	9
		M	3	3	37
		U	0	0	0
	INDEX YEAR	2009	6	6	46
2010		0	0	0	

Table 1a cont. Number of Users, Number of Dispensings, and Total Days Supplied by Drug Product, Age Group, Sex, and Year for Pre-Existing Condition Group - Addiction

			Unique Patients	Dispensings	Total Days Supplied
Generic Buprenorphine - Oral	<i>TOTAL</i>	<i>TOTAL</i>	968	2,723	52,822
	AGE GROUP	0 to 17 years	3	3	6
		18 to 64 years	950	2,674	51,773
		65+ years	15	46	1,043
	SEX	F	461	1,407	26,916
		M	504	1,313	25,856
		U	3	3	50
	INDEX YEAR	2009	246	744	15,945
		2010	722	1,979	36,877
Generic Buprenorphine - Powder	<i>TOTAL</i>	<i>TOTAL</i>	3	41	736
	AGE GROUP	0 to 17 years	0	0	0
		18 to 64 years	3	41	736
		65+ years	0	0	0
	SEX	F	0	0	0
		M	3	41	736
		U	0	0	0
	INDEX YEAR	2009	1	17	463
		2010	2	24	273

Table 1b. Number of Users, Number of Dispensings, and Total Days Supplied by Drug Product, Age Group, Sex, and Year for Pre-Existing Condition Group - Pain

			Unique Patients	Dispensings	Total Days Supplied
Buprenex	<i>TOTAL</i>	<i>TOTAL</i>	20	218	4,917
	AGE GROUP	0 to 17 years	0	0	0
		18 to 64 years	16	170	3,886
		65+ years	4	48	1,031
	SEX	F	7	85	1,965
		M	13	133	2,952
		U	0	0	0
	INDEX YEAR	2009	16	195	4,337
		2010	4	23	580
Butrans	<i>TOTAL</i>	<i>TOTAL</i>	0	0	0
	AGE GROUP	0 to 17 years	0	0	0
		18 to 64 years	0	0	0
		65+ years	0	0	0
	SEX	F	0	0	0
		M	0	0	0
		U	0	0	0
	INDEX YEAR	2009	0	0	0
		2010	0	0	0
Suboxone	<i>TOTAL</i>	<i>TOTAL</i>	10,967	71,627	1,541,276
	AGE GROUP	0 to 17 years	20	94	1,342
		18 to 64 years	10,669	70,361	1,512,527
		65+ years	278	1,172	27,407
	SEX	F	5,094	31,066	667,887
		M	5,858	40,491	871,943
		U	15	70	1,446
	INDEX YEAR	2009	7,473	54,569	1,211,208
		2010	3,494	17,058	330,068

Table 1b cont. Number of Users, Number of Dispensings, and Total Days Supplied by Drug Product, Age Group, Sex, and Year for Pre-Existing Condition Group - Pain

			Unique Patients	Dispensings	Total Days Supplied
Subutex	TOTAL	TOTAL	1,123	3,808	73,658
	AGE GROUP	0 to 17 years	1	3	90
		18 to 64 years	1,090	3,720	71,672
		65+ years	32	85	1,896
	SEX	F	603	2,151	41,694
		M	519	1,650	31,748
		U	1	7	216
	INDEX YEAR	2009	880	3,202	63,321
2010		243	606	10,337	
Generic Buprenorphine - Injectable	TOTAL	TOTAL	10	14	208
	AGE GROUP	0 to 17 years	0	0	0
		18 to 64 years	7	8	81
		65+ years	3	6	127
	SEX	F	7	11	131
		M	3	3	77
		U	0	0	0
	INDEX YEAR	2009	7	9	131
2010		3	5	77	
Generic Buprenorphine - Oral	TOTAL	TOTAL	719	1,745	34,604
	AGE GROUP	0 to 17 years	1	1	3
		18 to 64 years	691	1,680	33,085
		65+ years	27	64	1,516
	SEX	F	354	841	16,238
		M	363	902	18,346
		U	2	2	20
	INDEX YEAR	2009	167	452	10,661
2010		552	1,293	23,943	
Generic Buprenorphine - Powder	TOTAL	TOTAL	10	92	2,465
	AGE GROUP	0 to 17 years	0	0	0
		18 to 64 years	10	92	2,465
		65+ years	0	0	0
	SEX	F	6	44	1,160
		M	4	48	1,305
		U	0	0	0
	INDEX YEAR	2009	7	85	2,255
2010		3	7	210	

Table 1c. Number of Users, Number of Dispensings, and Total Days Supplied by Drug Product, Age Group, Sex, and Year for Pre-Existing Condition Group - Other

			Unique Patients	Dispensings	Total Days Supplied
Buprenex	<i>TOTAL</i>	<i>TOTAL</i>	5	24	480
	AGE GROUP	0 to 17 years	0	0	0
		18 to 64 years	5	24	480
		65+ years	0	0	0
	SEX	F	2	3	40
		M	3	21	440
		U	0	0	0
	INDEX YEAR	2009	5	24	480
2010		0	0	0	
Butrans	<i>TOTAL</i>	<i>TOTAL</i>	0	0	0
	AGE GROUP	0 to 17 years	0	0	0
		18 to 64 years	0	0	0
		65+ years	0	0	0
	SEX	F	0	0	0
		M	0	0	0
		U	0	0	0
	INDEX YEAR	2009	0	0	0
2010		0	0	0	
Suboxone	<i>TOTAL</i>	<i>TOTAL</i>	6,520	46,388	969,098
	AGE GROUP	0 to 17	43	255	4,172
		18 to 64	6,381	45,598	953,180
		65+	96	535	11,746
	SEX	F	3,030	21,020	427,620
		M	3,469	25,268	539,475
		U	21	100	2,003
	INDEX YEAR	2009	4,352	35,220	757,422
2010		2,168	11,168	211,676	
Subutex	<i>TOTAL</i>	<i>TOTAL</i>	624	2,473	44,885
	AGE GROUP	0 to 17 years	4	9	198
		18 to 64 years	611	2,434	43,872
		65+ years	9	30	815
	SEX	F	327	1,429	25,151
		M	297	1,044	19,734
		U	0	0	0
	INDEX YEAR	2009	473	2,074	39,079
2010		151	399	5,806	
Generic Buprenorphine - Injectable	<i>TOTAL</i>	<i>TOTAL</i>	5	5	39
	AGE GROUP	0 to 17 years	0	0	0
		18 to 64 years	5	5	39
		65+ years	0	0	0
	SEX	F	2	2	2
		M	3	3	37
		U	0	0	0
	INDEX YEAR	2009	5	5	39
2010		0	0	0	

Table 1c cont. Number of Users, Number of Dispensings, and Total Days Supplied by Drug Product, Age Group, Sex, and Year for Pre-Existing Condition Group - Other

			Unique Patients	Dispensings	Total Days Supplied
Generic Buprenorphine - Oral	<i>TOTAL</i>	<i>TOTAL</i>	454	1,281	22,973
	AGE GROUP	0 to 17	0	0	0
		18 to 64	451	1,277	22,853
		65+	3	4	120
	SEX	F	226	640	10,902
		M	226	639	12,051
		U	2	2	20
	INDEX YEAR	2009	104	346	7,512
		2010	350	935	15,461
Generic Buprenorphine - Powder	<i>TOTAL</i>	<i>TOTAL</i>	1	1	60
	AGE GROUP	0 to 17	0	0	0
		18 to 64	1	1	60
		65+	0	0	0
	SEX	F	0	0	0
		M	1	1	60
		U	0	0	0
	INDEX YEAR	2009	0	0	0
		2010	1	1	60

Table 2a. Number of Users by Drug Product, Age Group, and Pre-Existing Condition Group

Pre-Existing Condition Group	Age Group	Buprenex	Butrans	Suboxone	Subutex	Generic Buprenorphine - Injectable	Generic Buprenorphine - Oral	Generic Buprenorphine - Powder
ADDICTION	<i>TOTAL</i>	5	0	18,737	1,410	6	968	3
	0 to 17 years	0	0	91	6	0	3	0
	18 to 64 years	5	0	18,453	1,381	6	950	3
	65+ years	0	0	193	23	0	15	0
PAIN	<i>TOTAL</i>	20	0	10,967	1,123	10	719	10
	0 to 17 years	0	0	20	1	0	1	0
	18 to 64 years	16	0	10,669	1,090	7	691	10
	65+ years	4	0	278	32	3	27	0
OTHER	<i>TOTAL</i>	5	0	6,520	624	5	454	1
	0 to 17 years	0	0	43	4	0	0	0
	18 to 64 years	5	0	6,381	611	5	451	1
	65+ years	0	0	96	9	0	3	0

Table 2b. Number of Users by Drug Product, Sex, and Pre-Existing Condition Group

Pre-Existing Condition Group	Sex	Buprenex	Butrans	Suboxone	Subutex	Generic Buprenorphine - Injectable	Generic Buprenorphine - Oral	Generic Buprenorphine - Powder
ADDICTION	<i>TOTAL</i>	5	0	18,737	1,410	6	968	3
	Female	2	0	7,250	733	3	461	0
	Male	3	0	11,446	677	3	504	3
	Unknown	0	0	41	0	0	3	0
PAIN	<i>TOTAL</i>	20	0	10,967	1,123	10	719	10
	Female	7	0	5,094	603	7	354	6
	Male	13	0	5,858	519	3	363	4
	Unknown	0	0	15	1	0	2	0
OTHER	<i>TOTAL</i>	5	0	6,520	624	5	454	1
	Female	2	0	3,030	327	2	226	0
	Male	3	0	3,469	297	3	226	1
	Unknown	0	0	21	0	0	2	0

Table 3a. Total Days Supplied by Drug Product, Age Group, and Pre-Existing Condition Group

Pre-Existing Condition Group	Age Group	Buprenex	Butrans	Suboxone	Subutex	Generic Buprenorphine - Injectable	Generic Buprenorphine - Oral	Generic Buprenorphine - Powder
ADDICTION	TOTAL	1,020	0	3,236,579	109,902	46	52,822	736
	0 to 17 years	0	0	9,380	288	0	6	0
	18 to 64 years	1,020	0	3,200,080	107,277	46	51,773	736
	65+ years	0	0	27,119	2,337	0	1,043	0
PAIN	TOTAL	4,917	0	1,541,276	73,658	208	34,604	2,465
	0 to 17 years	0	0	1,342	90	0	3	0
	18 to 64 years	3,886	0	1,512,527	71,672	81	33,085	2,465
	65+ years	1,031	0	27,407	1,896	127	1,516	0
OTHER	TOTAL	480	0	969,098	44,885	39	22,973	60
	0 to 17 years	0	0	4,172	198	0	0	0
	18 to 64 years	480	0	953,180	43,872	39	22,853	60
	65+ years	0	0	11,746	815	0	120	0

Table 3b. Total Days Supplied by Drug Product, Sex, and Pre-Existing Condition Group

Pre-Existing Condition Group	Sex	Buprenex	Butrans	Suboxone	Subutex	Generic Buprenorphine - Injectable	Generic Buprenorphine - Oral	Generic Buprenorphine - Powder
ADDICTION	TOTAL	1,020	0	3,236,579	109,902	46	52,822	736
	Female	139	0	1,176,764	63,298	9	26,916	0
	Male	881	0	2,054,277	46,604	37	25,856	736
	Unknown	0	0	5,538	0	0	50	0
PAIN	TOTAL	4,917	0	1,541,276	73,658	208	34,604	2,465
	Female	1,965	0	667,887	41,694	131	16,238	1,160
	Male	2,952	0	871,943	31,748	77	18,346	1,305
	Unknown	0	0	1,446	216	0	20	0
OTHER	TOTAL	480	0	969,098	44,885	39	22,973	60
	Female	40	0	427,620	25,151	2	10,902	0
	Male	440	0	539,475	19,734	37	12,051	60
	Unknown	0	0	2,003	0	0	20	0

Table 4a. Number of Dispensings by Drug Product, Age Group, and Pre-Existing Condition Group

Pre-Existing Condition Group	Age Group	Buprenex	Butrans	Suboxone	Subutex	Generic Buprenorphine - Injectable	Generic Buprenorphine - Oral	Generic Buprenorphine - Powder
ADDICTION	<i>TOTAL</i>	58	0	150,076	5,812	6	2,723	41
	0 to 17 years	0	0	490	12	0	3	0
	18 to 64 years	58	0	148,437	5,710	6	2,674	41
	65+ years	0	0	1,149	90	0	46	0
PAIN	<i>TOTAL</i>	218	0	71,627	3,808	14	1,745	92
	0 to 17 years	0	0	94	3	0	1	0
	18 to 64 years	170	0	70,361	3,720	8	1,680	92
	65+ years	48	0	1,172	85	6	64	0
OTHER	<i>TOTAL</i>	24	0	46,388	2,473	5	1,281	1
	0 to 17 years	0	0	255	9	0	0	0
	18 to 64 years	24	0	45,598	2,434	5	1,277	1
	65+ years	0	0	535	30	0	4	0

Table 4b. Number of Dispensings by Drug Product, Sex, and Pre-Existing Condition Group

Pre-Existing Condition Group	Sex	Buprenex	Butrans	Suboxone	Subutex	Generic Buprenorphine - Injectable	Generic Buprenorphine - Oral	Generic Buprenorphine - Powder
ADDICTION	<i>TOTAL</i>	58	0	150,076	5,812	6	2,723	41
	Female	9	0	55,041	3,304	3	1,407	0
	Male	49	0	94,797	2,508	3	1,313	41
	Unknown	0	0	238	0	0	3	0
PAIN	<i>TOTAL</i>	218	0	71,627	3,808	14	1,745	92
	Female	85	0	31,066	2,151	11	841	44
	Male	133	0	40,491	1,650	3	902	48
	Unknown	0	0	70	7	0	2	0
OTHER	<i>TOTAL</i>	24	0	46,388	2,473	5	1,281	1
	Female	3	0	21,020	1,429	2	640	0
	Male	21	0	25,268	1,044	3	639	1
	Unknown	0	0	100	0	0	2	0

Table 5a. Days Supplied per User by Drug Product, Age Group, and Pre-Existing Condition Group

Pre-Existing Condition Group	Age Group	Buprenex	Butrans	Suboxone	Subutex	Generic Buprenorphine - Injectable	Generic Buprenorphine - Oral	Generic Buprenorphine - Powder
ADDICTION	<i>TOTAL</i>	204	.	173	78	8	55	245
	0 to 17 years	.	.	103	48	.	2	.
	18 to 64 years	204	.	173	78	8	54	245
	65+ years	.	.	141	102	.	70	.
PAIN	<i>TOTAL</i>	246	.	141	66	21	48	247
	0 to 17 years	.	.	67	90	.	3	.
	18 to 64 years	243	.	142	66	12	48	247
	65+ years	258	.	99	59	42	56	.
OTHER	<i>TOTAL</i>	96	.	149	72	8	51	60
	0 to 17 years	.	.	97	50	.	.	.
	18 to 64 years	96	.	149	72	8	51	60
	65+ years	.	.	122	91	.	40	.

Table 5b. Days Supplied per User by Drug Product, Sex, and Pre-Existing Condition Group

Pre-Existing Condition Group	Sex	Buprenex	Butrans	Suboxone	Subutex	Generic Buprenorphine - Injectable	Generic Buprenorphine - Oral	Generic Buprenorphine - Powder
ADDICTION	<i>TOTAL</i>	204	.	173	78	8	55	245
	Female	70	.	162	86	3	58	.
	Male	294	.	179	69	12	51	245
	Unknown	.	.	135	.	.	17	.
PAIN	<i>TOTAL</i>	246	.	141	66	21	48	247
	Female	281	.	131	69	19	46	193
	Male	227	.	149	61	26	51	326
	Unknown	.	.	96	216	.	10	.
OTHER	<i>TOTAL</i>	96	.	149	72	8	51	60
	Female	20	.	141	77	1	48	.
	Male	147	.	156	66	12	53	60
	Unknown	.	.	95	.	.	10	.

Table 6a. Dispensings per User by Drug Product, Age Group, and Pre-Existing Condition Group

Pre-Existing Condition Group	Age Group	Buprenex	Butrans	Suboxone	Subutex	Generic Buprenorphine - Injectable	Generic Buprenorphine - Oral	Generic Buprenorphine - Powder
ADDICTION	<i>TOTAL</i>	12	.	8	4	1	3	14
	0 to 17 years	.	.	5	2	.	1	.
	18 to 64 years	12	.	8	4	1	3	14
	65+ years	.	.	6	4	.	3	.
PAIN	<i>TOTAL</i>	11	.	7	3	1	2	9
	0 to 17 years	.	.	5	3	.	1	.
	18 to 64 years	11	.	7	3	1	2	9
	65+ years	12	.	4	3	2	2	.
OTHER	<i>TOTAL</i>	5	.	7	4	1	3	1
	0 to 17 years	.	.	6	2	.	.	.
	18 to 64 years	5	.	7	4	1	3	1
	65+ years	.	.	6	3	.	1	.

Table 6b. Dispensings per User by Drug Product, Sex, and Pre-Existing Condition Group

Pre-Existing Condition Group	Sex	Buprenex	Butrans	Suboxone	Subutex	Generic Buprenorphine - Injectable	Generic Buprenorphine - Oral	Generic Buprenorphine - Powder
ADDICTION	<i>TOTAL</i>	12	.	8	4	1	3	14
	Female	5	.	8	5	1	3	.
	Male	16	.	8	4	1	3	14
	Unknown	.	.	6	.	.	1	.
PAIN	<i>TOTAL</i>	11	.	7	3	1	2	9
	Female	12	.	6	4	2	2	7
	Male	10	.	7	3	1	2	12
	Unknown	.	.	5	7	.	1	.
OTHER	<i>TOTAL</i>	5	.	7	4	1	3	1
	Female	2	.	7	4	1	3	.
	Male	7	.	7	4	1	3	1
	Unknown	.	.	5	.	.	1	.

Table 7a. Days Supplied per Dispensing by Drug Product, Age Group, and Pre-Existing Condition Group

Pre-Existing Condition Group	Age Group	Buprenex	Butrans	Suboxone	Subutex	Generic Buprenorphine - Injectable	Generic Buprenorphine - Oral	Generic Buprenorphine - Powder
ADDICTION	<i>TOTAL</i>	18	.	22	19	8	19	18
	0 to 17 years	.	.	19	24	.	2	.
	18 to 64 years	18	.	22	19	8	19	18
	65+ years	.	.	24	26	.	23	.
PAIN	<i>TOTAL</i>	23	.	22	19	15	20	27
	0 to 17 years	.	.	14	30	.	3	.
	18 to 64 years	23	.	21	19	10	20	27
	65+ years	21	.	23	22	21	24	.
OTHER	<i>TOTAL</i>	20	.	21	18	8	18	60
	0 to 17 years	.	.	16	22	.	.	.
	18 to 64 years	20	.	21	18	8	18	60
	65+ years	.	.	22	27	.	30	.

Table 7b. Days Supplied per Dispensing by Drug Product, Sex, and Pre-Existing Condition Group

Pre-Existing Condition Group	Sex	Buprenex	Butrans	Suboxone	Subutex	Generic Buprenorphine - Injectable	Generic Buprenorphine - Oral	Generic Buprenorphine - Powder
ADDICTION	<i>TOTAL</i>	18	.	22	19	8	19	18
	Female	15	.	21	19	3	19	.
	Male	18	.	22	19	12	20	18
	Unknown	.	.	23	.	.	17	.
PAIN	<i>TOTAL</i>	23	.	22	19	15	20	27
	Female	23	.	21	19	12	19	26
	Male	22	.	22	19	26	20	27
	Unknown	.	.	21	31	.	10	.
OTHER	<i>TOTAL</i>	20	.	21	18	8	18	60
	Female	13	.	20	18	1	17	.
	Male	21	.	21	19	12	19	60
	Unknown	.	.	20	.	.	10	.

Appendix A. ICD-9-CM Codes for Each Pre-Existing Condition Group

Pre-Existing Condition	ICD-9 Code	Description	Pre-Existing Condition	ICD-9 Code	Description	
ADDICTION	3040	OPIOID TYPE DEPENDENCE	OTHER	3000	ANXIETY STATES	
	3051	TOBACCO USE DISORDER		2967	BIPOLAR AFFECTIVE NOS	
	3055	OPIOID ABUSE		3028	PSYCHOSEXUAL DIS NEC	
	3059	DRUG ABUSE NEC/NOS		3004	NEUROTIC DEPRESSION	
	3049	DRUG DEPENDENCE NOS		2966	BIPOLAR AFFECTIVE, MIXED	
	3043	CANNABIS DEPENDENCE		V703	MED EXAM NEC-ADMIN PURP	
	3048	COMB DRUG DEPENDENCE NEC		3140	ATTENTION DEFICIT DIS	
	3046	DRUG DEPENDENCE NEC		V654	OTH COUNSELING NEC	
	2920	DRUG WITHDRAWAL SYNDROME				
	3047	OPIOID/OTHER DRUG DEPEND				
	3050	ALCOHOL ABUSE				
	3042	COCAINE DEPENDENCE				
	3039	ALCOHOL DEPEND NEC/NOS				
	3052	CANNABIS ABUSE				
	3044	AMPHETAMINE DEPENDENCE				
	V681	ISSUE REPEAT PRESCRIPT				
	PAIN	7291	MYALGIA AND MYOSITIS NOS			
		7228	POSTLAMINECTOMY SYNDROME			
5559		REGIONAL ENTERITIS NOS				
7140		RHEUMATOID ARTHRITIS				
7242		LUMBAGO				
7890		ABDOMINAL PAIN				
7225		THORAC/LUMBAR DISC DEGEN				
7561		ANOMALIES OF SPINE				
7234		BRACHIAL NEURITIS NOS				
2500		DIABETES MELLITUS UNCOMP				
3382		CHRONIC PAIN NOS				
7210		CERVICAL SPONDYLOSIS				
3569		IDIO PERIPH NEURPTHY NOS				
3460		CLASSICAL MIGRAINE				
7221		THORAC/LUMB DISC DISPLAC				
7213		LUMBOSACRAL SPONDYLOSIS				
7243		SCIATICA				
7245		BACKACHE NOS				
7159		OSTEOARTHROSIS NOS				
3383		NEOPL RELAT PAIN AC & CH				
7880		RENAL COLIC				
5920		CALCULUS OF KIDNEY				